XXXX mutation and its relation to left @entity715 in chronic nonrheumatic @entity955 .

@entity5337 @entity1 @entity49 @entity955 @entity715
The genetic defect of @entity5337 , known as @entity5337 , produces a resistance to degradation by activated protein C and @entity49 . However, the role of @entity5337 in the formation of left @entity715 with nonrheumatic @entity955 has not been studied. We investigated whether @entity5337 is a risk factor for left @entity715 in @entity1 with nonrheumatic @entity955 . We analyzed clinical, echocardiographic, and biochemical data in 105 consecutive @entity1 with nonrheumatic @entity955 . These @entity1 were divided into two groups: group A (n = 37) with left @entity715 and group B (n = 68) without left @entity715 . The study also included 42 control subjects. Left @entity715 was investigated by using both transthoracic echocardiography and transesophageal echocardiography. Blood samples from the @entity1 and controls were analyzed for the @entity5337 mutation by DNA analysis, using the polymerase chain reaction. There was no significant difference in the prevalence of @entity5337 between the @entity1 and control subjects. The prevalence of @entity5337 mutation was 8.1% (3/37) in @entity1 with left @entity715 , and 8.8% (6/68) in @entity1 without left @entity715 . The prevalence of @entity5337 was 7.1% (3/42) in control subjects. The prevalance of @entity5337 was 10% (2/20) in @entity1 with spontaneous echo contrast and 8% (7/85) in @entity1 without spontaneous echo contrast. Multivariate analyses showed that left ventricular ejection fraction was an independent predictor of left @entity715 . @entity5337 mutation is not a risk factor for left @entity715 formation and spontaneous echo contrast in @entity1 with nonrheumatic @entity955 .
